新闻

(RTTNews) - Shares of Catalyst Pharmaceuticals, Inc. (CPRX) are climbing over 3 percent on Wednesday after the announcement of commercial launch of Agamree in the U.S.

The drug was authorized by the U.S. Food and Drug Administration for the treatment of patients aged two years and older suffering from duchenne muscular dystrophy, a rare and life-threatening neuromuscular disorder.

Currently, Catalyst's stock is trading at $16.71, up 3.15 percent over the previous close of $16.20 on the volume of 275,766 on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.